A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in…
A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study
- Promotore
- GlaxoSmithKline Biologicals S.A.
- Acronimo
- RSV OA=ADJ-012
- Struttura
- Riabilitazione respiratoria
- Sperimentatore principale
- De Michelis Valter Mario
- Stato arruolamento
- Arruolamento in corso
- Unit di ricerca
- Medicina Riabilitativa